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Summary Improvements to the original procedure of using a panel of monoclonal antibodies and magnetic
microspheres for the depletion of tumour cells from bone marrow are described. These include a completely
disposable system for the magnetic depletion of tumour cells coated with magnetic microspheres. Properties of
a new series of microspheres are compared with the old M330 beads in their ability to deplete neuroblasts
from both model systems and 50 bone marrows harvested from Stage IV neuroblastoma patients. Using
human neuroblastoma cell lines labelled with the DNA intercalating, Hoechst dye 33342 a 5% tumour
contamination can routinely be removed from 5x 106-5 x 107 nucleated cells. Analysis of the 50 purged
marrows revealed that 10 were visibly contaminated with tumour (by conventional cytology and
immunological procedures). In all but one case, tumour cells were removed. In this instance the tumour:bead
ratio fell to 1:4 indicating the importance of maintaining a sufficient number of beads in the system. Red cell
contamination of marrow was also kept extremely low so preventing possible physical blockade of
bead:tumour cell interaction. Marrow engraftment was rapid in this group, apart from patients who had been
exposed to high doses of alkylating agents prior to autografting.
A variety of techniques have been developed to
deplete tumour cells from bone marrow harvested
for autologous transplantation (Treleaven et al.,
1985). Of these, four have been used either experi-
mentally or clinically for the removal of neuroblasts
from marrow taken from children with Evans stage
IV neuroblastoma (Evans et al., 1971). Reisner
(1983) has shown that, in model systems, he could
obtain a limited depletion of neuroblasts from bone
marrow using soybean agglutinin. Saarinen et al.
(1985) have described, in model systems, the use of
a murine monoclonal antibody of the IgG3 isotype
(recognising the ganglioside GD2) and human
complement for killing tumour cells in bone
marrow. However the use of a single antibody and
complement for purging marrow is unlikely to lead
to maximal tumour kill as Gee et al. (1986) have
demonstrated that this leads to the selection of cells
of low antigen density, resistant to complement
mediated cytolysis.
The derivative of cyclophosphamide, Asta Z, has
been used to 'chemically purge' neuroblasts from
bone marrow harvested for autologous transplanta-
tion (Douay, 1985). Whilst this is effective in model
systems using relatively rapidly dividing cell lines, it
may not efficiently kill fresh neuroblastoma cells,
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many of which may be in the GI/GO phase of the
cell cycle (Danon et al., 1980). Alternatives for the
chemical purging of neuroblasts from bone marrow
are dopamine and ascorbic acid (Reynolds et al.,
1982) and the analogue of epinephrine/nor-
epinephrine, meta-iodobenzylguanidine radio-
labelled with 131-I (Buck et al., 1985). In addition
the photoactivation of merocyanine 540 which is
reported to be selectively taken up into the
membranes of certain leukaemic and neuroectoder-
mal cell lines is another approach to investigating
tumour cell kill in bone marrow (Sieber et al.,
1986).
The physical removal of neuroblastoma cells
from bone marrow using an elutriation centrifuge
has been described by Figdor et al., (1985). This
was reported capable of depleting only -90% of
tumour cells from marrow. An alternative physical
procedure is to use a panel of monoclonal anti-
bodies and magnetic microspheres (Treleaven et al.,
1984). This is effective for the removal of neuro-
blastoma cell lines and fresh neuroblasts from bone
marrow with an efficiency of at least three
logarithmic units of tumour depletion (Treleaven et
al., 1984). An indirect approach to targetting
microspheres to tumour cells has been adopted.
Initially monoclonal antibodies are added to
contaminated bone marrow and these bind
selectively to the tumour cells. Microspheres coated
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with anti-mouse Ig are then added to the system
which bind to the antibody-coated cells. (Treleaven
et al., 1984).
Over the last two years the original method for
the depletion of neuroblastoma cells from bone
marrow has been considerably modified. Here we
detail these modifications and report on the first 50
marrows from neuroblastoma patients treated by
this technique. This represents - 30% of the total
'magnetic' marrow purges that have been under-
taken for neuroblastoma and other malignancies in
the collaborative groups investigating this
technique.
Materials and methods
Preparation ofmicrospheres
Both the M330 and 450 series of microspheres are
magnetic polymer beads of uniform size prepared
by the method of Ugelstad et al. (1984). To obtain
a monodispersed preparation of microspheres, sus-
pensions of M330 microspheres were sonicated as
described previously (Treleaven et al., 1984).
Preparations containing individually separate beads
were prepared by simply shaking the M450 micro-
spheres in PBS. Both series of microspheres were
washed 3 times in alcohol for sterilisation and
incubated overnight with sheep anti-mouse
immunoglobulin (Ig) in PBS (pH 7.7) for 18 h at
4°C. The microspheres were washed using PBS
containing 10% v/v human plasma protein (PPF)
(4.5% albumin) directly before use to remove
unbound anti-mouse Ig.
Collection ofbone marrow andpreparation ofa
buffy coatfraction.
Bone marrow was harvested from either/both iliac
crest(s) under general anaesthetic and trans-
ferred to culture medium containing preserva-
tive-free heparin (final concentration 4Uml-1).
Buffy coat fractions were prepared using either a
IBM (Cobe) 221 or the Erytrenn cell separator
(Biotest). Care was taken to reduce the red cell
contamination of the buffy coat fraction to a
minimum, without excessive loss of nucleated cells.
If this was not achieved during the initial
separation a further buffy coat was prepared when
excess antibody was washed from the bone marrow
(see Results).
Monoclonal anitbodies and incubation ofbone
marrow with anti-mouse Ig coated microspheres
A panel of purified monoclonal antibodies,
selectively binding to neuroblastoma, were added to
the buffy coat fraction of bone marrow as
described previously (Treleaven et al., 1984).
Following incubation for 30min at 4°C, the
marrow was washed free of excess antibody and
transferred to a 600ml transfer bag (Travenol Lab.,
U.K.). M330 microspheres (100mg) or a minimum
of 150mg of M450 microspheres were added to the
marrow, and the bag gently rotated for 30min at
4°C. Sufficient volume of RPMI 1640 tissue culture
medium containing 10% PPF was added to the
marrow to give a packed volume of cells no greater
than 10%.
Magnetic cell separation.
The system currently in use is an adaptation of the
original flow system, now employing disposable
magnetic separation chambers. These are made
from gambrohemofreeze bags. A heat sealer was
used to reduce the volume of the bags to -30ml.
Two of these modified 'chambers' were linked using
a disposable Travenol 2243 connector. Fourteen
samarium cobalt magnets were placed under the
cham.bers as illustrated in Figure 1. The treated
marrow was attached to the first chamber using a
Travenol 2243 line. The marrow was 'pulled'
through the system at a constant rate of
2.5 mlmin- I using a peristaltic pump. This was
placed after the magnetic separation chambers to
avoid disruption of the tumour cell/bead complexes.
The separation chambers and marrow were kept at
4°C during the purging procedure. A Travenol 2244
connector was used to link the last chamber to the
pump and a similar connector used to attach a
Travenol 600ml transfer pack to the apparatus to
collect marrow purged of tumour. The chambers
were flushed free of haemopoietic progenitors using
saline containing 10% PPF v/v to maximise cell
yields.
Tumour cell depletion and assessment of
haemopoietic progenitor recovery
In the model system studied neuroblastoma cells
were initially incubated with the DNA binding dye
Hoechst 33342 according to the method of
Reynolds et al. (1985). These were titrated into
either peripheral blood or bone marrow at different
percentages (1-10%). Removal of tumour cells
from the system was determined by estimating the
number of fluorescent cells remaining in the cell
mixture under UV fluorescent microscopy. Before
analysis samples were mixed with trypan blue to
exclude the possibility of dye being taken up by
dead cells.
Tumour cell removal from fresh bone marrow
was determined by indirect immunofluorescence
using monoclonal antibodies and fluorescein con-
jugated sheep anti-mouse Ig. Several antibodiesDEPLETION OF NEUROBLASTOMA FROM MARROW
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Figure 1 The flow system incorporating disposable chambers and samarium cobalt magnets for the depletion
of tumour cells from bone marrow.
used in this study [PI153/3 (Kennett & Gilbert,
1979), A2B5 (Eisenbarth et al., 1979), UJ167.11,
UJ223.8] were not employed in the magnetic
depletion procedure. Assays for haemopoietic
progenitor cells, (CFUc, BFUe and CFUgem) were
undertaken according to the method of Fausner
and Messner (1979). Samples were also checked for
bacterial and fungal contamination in the
Bacteriology Dept., Hospital for Sick Children.
Results
Magnetic microspheres
The properties of the new M450 microspheres are
listed in Table I. Unlike the M330 series of micro-
spheres the M450 beads become completely mono-
dipersed upon suspension in either water or PBS
(no sonication needed). They are resistant to most
organic solvents enabling them to be rapidly
sterilised. Like the 330 series of beads which they
replace, they are uniform, both in size and in the
amount of magnetite they contain (Figure 2A). The
major functional differences in the M450 micro-
spheres over the old beads are a 5-fold reduction in
the number of beads/mg, and a 30-fold reduction in
their surface area (Table I). This reduces consider-
Table I Properties of the microspheres used for tumour
cell depletion.
Original New
Microspheres microspheres
(M330) (M450)
Size 3pum 4.5pm
Particles (mg) 7.9x 107 1.4x 107
Surface area 100-150mg - 3-5mg -
Monodispersal
without sonication No Yes
Ig binding
for depletion 100mgIgg-1 <0mglgg-1
studies microspheres microspheres
Stability of binding
over 7 days >95% >95%
Ability to covalently
link antibody No Yes
ably the amount of protein needed to saturate
protein binding sites on the microspheres. Only
6mgIgg-1 beads will result in maximal protein
binding, 15 times less than that used with the M330
series. However due to the reduction of the number
of beads mg-1 (Table I) to' maintain a
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Figure 3 A comparison of the recovery of nucleated
WBC after depleting bone marrow of tumour cells
using either M330 or M450 microspheres. 1 buffy
coat fraction; O after tumour depletion.
was kept as low as possible and calculated to be no
more than 50-80 RBC/nucleated WBC. Recovery
of nucleated cells after preparation of the buffy
coat was found to be -64% (range 40-130%;
n =50).
Figure 2 A. Scanning electron micrograph of the
M450 series of microspheres illustrating uniformity
and monodispersal. Magnification x 8000. B. Scanning
electron micrograph of microspheres binding to
neuroblastoma cells. Magnification x 2000.
bead:tumour ratio of -30:1 increased quantities of
beads need to be used in the purging procedure (see
below). An overall saving of 70-80% of anti-mouse
Ig can however be made using the M450 rather
than the M330 microspheres.
Preparation ofbuffy coatfractionsfrom bone
marrow
Although it was aimed to harvest 3 x 108 nucleated
cellskg-1 body wt from each patient, considerable
variations in cell counts were obtained (1.1-
8.0 x 108 kg '; n = 50). Volumes of harvested
marrow ranged from 150-850ml. For volumes
<400ml the Erytrenn cell separator was used in
preference to the IBM apparatus for buffy coat
preparation. The relatively large capacity of the
IBM 2991 bag (650ml) makes this difficult to use
with small volumes of bone marrow without adding
a dense inert fluid, e.g. glycerol, to reduce the
internal capacity of the bag. Red cell contamination
Haemopoietic cell recoveries
Figure 3 shows that purging marrow of neuro-
blastoma cells with either the M330 series of micro-
spheres (n = 14) or the M450 beads (n =36) results
in similar losses of cells. In both instances a mean
of 65-70% of nucleated cells were recovered,
although considerable variation in the percentage
recoveries were noted (M330 beads, 42-111%;
M450 series, 38-87%). Recovery of cells was
independent of the original cell count and although
several marrows were contaminated with tumour
cells these could not account for the overall losses
observed.
Studies on colony assays pre and post separation
with antibodies and either series of microspheres
showed a small but non-selective loss of
haemopoietic progenitors per 105 mononuclear cells
(Table II). No significant difference was noted in
the losses observed using either M330 or M450
microspheres. Whilst the number of marrows
purged with the magnetic bead technique was 50 in
total, colony assay data were only available in full
for 33 due to sample losses, infections and assay
failures.
Depletion efficiency
Using model experiments to determine the
efficiency of detecting Hoechst labelled neuro-
0-
M450
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Table II Comparison of bone marrow harvested for patients with neuroblastoma
treated with a panel of monoclonal antibodies and either M330 or M450
microspheres.
CFUc x 105 BFUe x 105 CFUgem x 105
mononuclear mononuclear mononuclear
cells cells cells
Mean Range Mean Range Mean Range
Original microspheres M330
Buffy
fraction 110 (27-211) 33.5 (2-81) 5 (0-22)
Post
treatment 93.5 (2-208) 22.5 (0-56) 5 (0-26)
% recovery 84 67 76
n 13 13 12
New microspheres M450
Buffy
fraction 150 (43-343) 19.6 (6-40) 3.6 (0-20)
Post
treatment 126 (27-354) 17.8 (1-50) 2.8 (0-6)
% recovery 84 90.8 77
n 27 24 21
blastoma cells titrated into peripheral blood mono-
nuclear cells or bone marrow we routinely
identified one malignant cell in 10,000 normal
nucleated progenitors. In depletion experiments 1,
5, 10, 20% Hoechst labelled cells were titrated into
between 5 x 106 and 5 x 104 normal cells. One mg
of either M330 or M450 microspheres was used to
deplete tumour cells from the population after
incubation with anti-neuroblastoma monoclonal
antibodies. Microscopic examination of multiple
fields (>20,000 cells) did not identify residual
neuroblasts in samples containing 1 or 5% of
tumour cells (Figure 2.B). This was found to be the
case for both the M330 and 450 microspheres. In
these experiments as the tumour burden in the
marrow was increased the number of beads added
was kept constant. Therefore the ratio of beads to
tumour cells fell 20 times during the experiments.
Occasional fluorescent tumour cells were identified
in the marrow/blood, mononuclear cells originally
contaminated with 10% and 20% neuroblasts.
Here, using the M450 microspheres the
bead: tumour ratio became as low as 3: 1. No
attempts were made to increase the efficiency of the
depletion technique at these levels of tumour
contamination as it was not felt to be clinically
relevant.
Of the 50 marrow purges reviewed 10 were
undertaken on marrows that were contaminated
with tumour cells (as identified by conventional
cytology and immunohistology). Tumour cell con-
tamination ranged from approximately 1-7%
(Table III). In all of these cases except one, tumour
cells were removed from the marrow after
incubation with monoclonal antibodies and
magnetic microspheres. In this instance the ratio of
beads to tumour cells was 4:1. This occurred as
the marrow was not tested for the degree of tumour
cell involvement prior to the purging procedure.
Whilst efficient tumour purging occurred with
M450 beads at bead:tumour ratios of - 12-17:1,
Table III Removal of neuroblastoma cells from bone
marrow using a panel of monoclonal antibodies and two
different types of magnetic microspheres.
Estimated % Ratio beads:
tumour cells tumour cells Cells detected'
Beads in buffy coat in buffy coat after purge
M330 2 131:1 None
M330 2 92:1 None
M330 1 63:1 None
M330 1 114:1 None
M450 2 24:1 None
M450 2 17:1 None
M450 2.5 12:1 None
M450 7 4:1 2%
M450 1.5 46:1 None
M450 1 38:1 None
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the errors involved in estimating the level of malig-
nant cell contamination in marrow are high. This is
due to the tumour clumps that are invariably found
in the marrow. Currently we allow 30 beads/tumour
cell as a minimum and this is increaced to >50: 1 if
red cell contamination cannot be reduced to the
levels illustrated above.
Reconstitution times
Of the 50 marrows purged, 10 patients have been
lost to follow up, many being children treated
outside the U.K. Six were marrows harvested from
children receiving high dose targeted radiation
therapy, and it was not necessary to use this for
autologous rescue (Kemshead et al., 1985). Two
patients relapsed between the marrow harvest and
the ablative therapy and treatment was not
continued. Ten marrows remain frozen to be used
at a later date in the childrens' management. Data
are available on 21 individuals of which 4
succumbed to infection prior to regraftment (within
30 days of giving the graft). This was not due to
contamination of the marrow during the purging
procedure as assessed by bacterial/fungal screening.
Thirteen of 17 patients were given a high dose
ablative protocol in first remission. Of these 6
marrows were purged using the M330 beads. The
mean time (T) for recovery to 500 neutrophils was
21.5 days (range 17-24) and 50,000 platelets 30.3
(range 19-43) days. The remaining 7 were purged
using the M450 microspheres and similar recovery
times were noted T-500 neutrophils, 22 days (range
14-36) and T 50,000 platelets, 33 days (range 19-
38). The remaining 4 patients who were grafted in
second remission, had considerably longer recovery
times (mean T500 neutrophils 46 days; mean
T50,000 platelets 81.5 days). All of these had been
previously exposed to relatively high doses of
alkylating agents, which presumably caused damage
to either marrow progenitors or stromal elements
associated with haemopoietic recovery.
It is not possible to acquire accurate data on the
survival of this group of patients as they have been
treated in different centres, using different induction
and ablative protocols (see Discussion).
Discussion
The use of magnetic microspheres and panels of
monoclonal antibodies for the depletion of tumour
cells from bone marrow is an extremely fast, effi-
cient and cost effective procedure (Treleaven et al.,
1984). The modifications described here represent
considerable improvements over the original
method, economising on reagents, the time involved
in the procedure, and allowing a completely dispos-
able system to be used for the magnetic separation
chambers. The indirect approach to depleting
tumour cells from bone marrow allows for the
saturation of antigen binding sites on malignant
cells, and attempts to overcome the problem of
antigen heterogeneity known to occur in tumour
cells (Kemshead et al., 1983).
Adaptations of the indirect procedure described
above are currently being explored by others in
experimental systems. Kvalheim et al. (personal
communication) is using high affinity IgM
antibodies directly conjugated to M450 micro-
spheres to deplete lymphoma cells from bone
marrow and Gee et al. (personal communication)
used anti-T and anti-neuroblastoma antibodies pre-
complexed with anti-mouse Ig coated microspheres
to remove T cells and neuroblasts from peripheral
blood and bone marrow respectively. Currently we
are exploring the use of magnetic microspheres
coated with material other than anti-mouse Ig.
Beads coated with Clq, a component of comple-
ment, can recognise antibody only when complexed
with antigen suggesting that these may be added to
bone marrow contaminated with tumour at the
same time as the panel of monoclonal antibodies
(Sawada et al., 1986).
The indirect system of depleting tumour cells
from bone marrow has been used to purge marrow
harvested from 14 children with acute lympho-
blastic leukaemia. Obviously in these cases a
different panel of antibodies has been applied to
the marrow. Whilst the reagents show very low
cross reactivity with cells in normal bone marrow
(<1%), the levels of nucleated cell and committed
haemopoietic cell progenitors recovered are
considerably and consistently lower than for the
neuroblastoma patients (Kemshead, in preparation).
These patients have engrafted well on the whole, but
the observation suggests that the use of different
antibodies with the magnetic microspheres may
considerably alter cell recoveries obtained and by
implication the efficiency of tumour cell removal.
No direct comparison of other purging pro-
cedures has been undertaken for neuroblastoma on
marrows used clinically, since in the laboratory
other procedures have produced results that are
inferior to the magnetic separation technique.
However, Favrot et al. (1985) have compared the
efficiency of antibody and complement and mag-
netic tumour cell depletion using marrow con-
taminated with Burkitt's lymphoma cell lines. Using
a modified system to that described above
employing a mononuclear cell fraction rather than
buffy coat and double depletion procedure, Favrot
and colleagues report a depletion efficiency of 4
logarithmic units which is equal to that achieved
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Whether buffy coat preparations are preferable to
mononuclear cell preparations for immunomagnetic
depletion remains controversial. Mononuclear cell
preparations have the advantage that the levels of
contaminating RBC are very low which thus avoids
physical inhibition of the binding of microspheres
to tumour cells. However cell losses are high and
the added complexity and time involved in the
preparation of a mononuclear cell fraction suggests
that, if sufficient red cell depletion of a buffy coat
fraction can be achieved, this would be the method
of choice. At red cell levels of 50-80 cells/nucleated
WBC and approximately the same ratio of micro-
spheres:tumour cells, no inhibition of beads binding
to neuroblasts was noted.
The M450 microspheres offer considerable
advantage over the old M330 beads and those
produced by other laboratories. These beads have
hydroxyl groups on their surface allowing mono-
clonal antibodies, anti-mouse Ig or other antibody
binding molecules to be covalently linked to the
surface of the microspheres. This should further
standardise the depletion technique used for
neuroblastoma in different laboratories.
The clinical need to purge bone marrow in Stage
IV neuroblastoma needs further evaluation. An
analysis of the group of patients treated in
association with this laboratory is difficult due to
the different induction protocols employed and the
different ablative regimens used in association with
the autograft. Preliminary results from our studies
and those of T. Philip (using standard induction
and ablative regimens) suggest that the role of high
dose chemo/radiotherapy in children with Stage IV
neuroblastoma is one of consolidation therapy for
children either in complete remission or having
minimal residual disease following conventional
combination chemotherapy. Where children are in
overt relapse or partial remission with a consider-
able tumour burden the high dose 'megatherapy'
given appears insufficient to ablate the tumour in
vivo. In these cases where relapse/progression often
occurs post megatherapy and transplantation,
active disease is almost invariably found at sites of
original disease although marrow involvement is
also often observed.
Although it is too early to be confident ofsurvival,
several children given high dose radio/chemotherapy
when in complete remission remain well over two
years post transplantation. The role of purging in
this group is difficult to establish. The known
patchy involvement of neuroblastoma in bone
marrow makes accurate detection of tumour
extremely difficult. In two cases of the 50 described
here, marrow aspirates appeared free of tumour
cells one month prior to the harvest for trans-
plantation and yet a heavy infiltrate was found
when the autograft was prepared. These obser-
vations provide the most compelling reasons for
purging marrow from Stage IV neuroblastoma
patients apparently in complete remission. The
current ablative regimens used in Stage IV neuro-
blastoma carry a considerable risk of toxicity. As
well as facilitating the clinical application of this
type of therapy, research efforts should continue to
improve the purging procedure and reduce overall
toxicity. This may be accomplished in the future by
the further in vivo use of monoclonal antibodies as
agents to target radioisotopes to minimal residual
disease. Toxicity of this type of therapy is currently
being assessed but it is likely to be considerably less
than the problem associated with giving external
beam total body irradiation to children.
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